Subscribe
Sunday, June 1, 2025
20.6 C
Bengaluru
type here...
Subscribe

Noumaan Qureshi

Noumaan Qureshi is pursuing a doctorate in communications and has been associated with the healthcare sector for close to two-and-half decades.
linkedin

Indian Pharmaceutical Innovation – Post TRIPS

Leaderspeak Noumaan Qureshi -
It is the twentieth anniversary of the new patent act in January 2025. The post-patent (P20) era is a story of resilience, determination, and charting a course that set global ambitions, a story of finding opportunity in adversity. It is a story for case studies in business schools, in international studies, in global health efforts.

Violence Against Medics – Lessons to Draw from Private Hospitals

Leaderspeak Noumaan Qureshi -
One interesting fact: most medical colleges and linked public hospitals in major cities were designed in the British era, with an open ward design. A medical administrator, tongue-in-cheek, put it succinctly: “When these hospitals were designed, nobody would have imagined that doctors will face violence”. Time for design thinking in public healthcare delivery!

Rethinking Healthcare Communications for the Indian Context

Leaderspeak Noumaan Qureshi -
Indian healthcare is sometimes an enigma: on one hand is the finest center of medical excellence, while on the...

72nd Republic Day: What’s the Road Ahead for Indian Pharma?

Leaderspeak Noumaan Qureshi -
“We are getting too happy, for too little”: these words of a senior pharma journalist a decade back sound...

Finding the middle ground for Doctor-Stakeholder Relationship

Leaderspeak Noumaan Qureshi -
Healthcare systems around the world differ – public, private or a mix of both public and private (like in India). With all the variance in healthcare delivery models, the risks to healthcare professionals remain universal: needle injuries to litigations to episodes of threats/ violence
spot_imgspot_img

MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More

Company

Headlines

Semaglutide – More Than Just a Patent Battle

0
The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

0
A New Era for Obesity Pills Novo Nordisk has announced...

Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?

0
Tata 1mg App Business Model: How does it work...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

0
In a bold move to strengthen its hepatology pipeline,...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2025 | Crafted by SlamDunk